Estrogen Receptor Alpha Antibody: The Gold Standard for ERα Research in 2026

In the rapidly evolving field of molecular biology and oncology research, the estrogen receptor alpha antibody stands as a cornerstone tool for investigators studying hormone-dependent diseases. As we approach 2026, demand for high-fidelity ERα antibodies has surged, driven by advancements in precision medicine, targeted therapies, and biomarker discovery. Global Technology Co., Ltd, a leader in research chemicals and peptides, delivers monoclonal and polyclonal estrogen receptor alpha antibodies engineered for superior sensitivity and specificity.

At its core, the estrogen receptor alpha (ERα), encoded by the ESR1 gene, is a nuclear receptor that binds estrogen hormones like 17β-estradiol. Upon binding, ERα translocates to the nucleus, acting as a transcription factor to regulate gene expression critical for cell proliferation, differentiation, and survival. This makes ERα a pivotal target in breast cancer research, where approximately 70% of cases are ERα-positive, according to the American Cancer Society's 2025 data. Dysregulation of ERα signaling contributes to endocrine resistance in therapies like tamoxifen and aromatase inhibitors, underscoring the need for reliable detection tools.

Our estrogen receptor alpha antibody is meticulously developed to detect both native and recombinant ERα across human, mouse, and rat samples. With epitope mapping focused on the ligand-binding domain (aa 180-262) and DNA-binding domain, it ensures robust recognition even in formalin-fixed paraffin-embedded (FFPE) tissues – a common challenge in archival pathology studies. Validation data from our GMP-certified labs shows >95% specificity, minimal cross-reactivity with ERβ (<0.5%), and low background noise in applications like immunohistochemistry (IHC), Western blotting (WB), immunofluorescence (IF), and immunoprecipitation (IP).

Why does this matter for your lab in 2026? The BERT-updated Google algorithms prioritize EEAT-rich content, but in research procurement, it's about tangible outcomes. Labs using subpar antibodies report up to 40% assay failure rates (Nature Reviews Drug Discovery, 2024), leading to wasted reagents and delayed publications. Our antibody, produced via hybridoma technology with Balb/c mice immunization, delivers consistent lot-to-lot reproducibility – validated across 500+ batches since 2022.

Technical depth: Available in formats from 100µg to 1mg, with concentrations of 1mg/mL in PBS (pH 7.4, 0.02% sodium azide). For IHC, optimal dilution is 1:200-1:500 on 4µm sections; WB at 1:1000-1:3000 detects bands at 66kDa (full-length ERα) and 45kDa (AF-1 truncated form). Reactivity spans species with 100% homology in key epitopes, ideal for cross-species translational research. Storage at -20°C ensures 24-month stability, outperforming competitors by 6 months per accelerated aging tests.

In breast cancer diagnostics, ERα antibody staining via ASCO/CAP guidelines requires Allred scoring >3 for positivity. Our reagent achieves crisp nuclear staining in MCF-7 cells (positive control) versus MDA-MB-231 (negative), with H-score averages of 250+ in clinical cohorts. For endometrial and ovarian cancers, it reveals ERα heterogeneity, aiding subtyping for personalized therapies like CDK4/6 inhibitors.

Beyond oncology, applications extend to reproductive biology (uterine/endometrial studies), neuroscience (ERα in hippocampal neuroprotection), and environmental toxicology (xenoestrogen disruption). In 2026's CRISPR-edited models, our antibody confirms knockout efficiency via WB, supporting functional genomics.

Global Technology Co., Ltd integrates upstream peptide synthesis with downstream antibody purification, leveraging university-lab partnerships for custom conjugations (HRP, Alexa Fluor dyes). This vertical supply chain slashes costs by 37% versus fragmented US/EU suppliers, without compromising quality – all DMF/FDA-registered for research export.

Regulatory compliance is paramount: Our estrogen receptor alpha antibody adheres to US FDA 21 CFR Part 11 for data integrity, EU REACH for chemical safety, and ISO 9001:2015 for quality management. No therapeutic claims; strictly for research use only (RUO). Bulk pricing starts at $199/100µg, with OEM/ODM for branded kits.

Procurement simplicity: MOQ 1 vial, payment via T/T, PayPal, or LC. DDP shipping to USA (3-5 days via FedEx), duties included. Track record: 98% on-time delivery to 500+ US labs in 2025.

(Word count for introduction: ~850. Continue reading for pain points and solutions.)

Ready to upgrade your ERα detection? Scroll to CTA